Yusuf Sherwani, M.D.
About Yusuf Sherwani, M.D.
Yusuf Sherwani, M.D. is the Co-Founder and CEO of Pelago, a digital health platform that integrates behavioral therapy with pharmacotherapy for substance use disorders. He has a medical degree and extensive experience in healthcare management, advocating for policy changes to enhance access to digital health solutions.
Work at Pelago
Yusuf Sherwani serves as the Co-Founder and CEO of Pelago, a position he has held since 2017. Under his leadership, Pelago has developed a digital platform that integrates behavioral therapy with pharmacotherapy specifically for substance use disorders. Sherwani has been instrumental in expanding Pelago's services to include management solutions for adolescent substance use. He has also led fundraising campaigns that secured significant investments for the company’s growth into new markets.
Education and Expertise
Yusuf Sherwani holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) and a Bachelor of Science (B.Sc. Hons) in Healthcare Management from Imperial College London. He furthered his education at Imperial College Business School, focusing on healthcare management. Additionally, he participated in the W18 Batch at Y Combinator in 2018. His educational background equips him with a deep understanding of both medical and management aspects of healthcare.
Background
Prior to his role at Pelago, Yusuf Sherwani worked at NHS England as a Clinical Entrepreneur Fellow from 2017 to 2020. He also served as a Clinical Research Scholar at Wellcome Trust for a brief period in 2014. His experience in these roles has contributed to his expertise in healthcare innovation and research, particularly in the area of substance use management.
Achievements
Yusuf Sherwani has co-authored a research paper focused on digital health interventions for substance use management. He has actively participated in discussions at national health conferences and the Digital Health Summit, advocating for policy changes to improve access to digital health solutions. His involvement in research related to substance use trends in the U.S. highlights his commitment to addressing challenges in substance use support, particularly for teens and adolescents.